Literature DB >> 17380128

Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F-1 after DNA damage.

Yasumichi Inoue1, Masatoshi Kitagawa, Yoichi Taya.   

Abstract

The retinoblastoma tumor suppressor protein (pRB) plays a critical role in the control of cell proliferation and in the DNA damage checkpoints. pRB inhibits cell cycle progression through interactions with the E2F family of transcription factors. Here, we report that DNA damage induced not only the dephosphorylation of pRB at Cdk phosphorylation sites and the binding of pRB to E2F-1, but also the phosphorylation of pRB at Ser612. Phosphorylation of pRB at Ser612 enhanced the formation of a complex between pRB and E2F-1. Substitution of Ser612 with Ala decreased pRB-E2F-1 binding and the transcriptional repression activity. Until now, Ser612 of pRB has been thought to be phosphorylated by Cdk2. However, the phosphorylation of pRB at Ser612 was conducted by Chk1/2 after DNA damage, and inhibition of ATM-Chk1/2 activity suppressed the phosphorylation of Ser612 and the binding of pRB to E2F-1. These results suggest that Ser612 is phosphorylated by Chk1/2 after DNA damage, leading to the formation of pRB-E2F-1. This is the first report that pRB is phosphorylated in vivo by a kinase other than Cdk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380128      PMCID: PMC1852778          DOI: 10.1038/sj.emboj.7601652

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

1.  Balance between acetylation and methylation of histone H3 lysine 9 on the E2F-responsive dihydrofolate reductase promoter.

Authors:  Estelle Nicolas; Christine Roumillac; Didier Trouche
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

2.  Generation and application of phospho-specific antibodies for p53 and pRB.

Authors:  Yoichi Taya; Kiichiro Nakajima; Kumiko Yoshizawa-Kumagaye; Katsuyuki Tamai
Journal:  Methods Mol Biol       Date:  2003

3.  Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach.

Authors:  Ted O'Neill; Lauren Giarratani; Ping Chen; Lakshmanan Iyer; Chang-Hun Lee; Matthew Bobiak; Fumihiko Kanai; Bin-Bing Zhou; Jay H Chung; Gary A Rathbun
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

4.  Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9.

Authors:  Kiyotsugu Yoshida; Hong-Gang Wang; Yoshio Miki; Donald Kufe
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

5.  The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.

Authors:  J Falck; N Mailand; R G Syljuåsen; J Bartek; J Lukas
Journal:  Nature       Date:  2001-04-12       Impact factor: 49.962

Review 6.  The retinoblastoma tumour suppressor in development and cancer.

Authors:  Marie Classon; Ed Harlow
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

Review 7.  The Chk2 protein kinase.

Authors:  Jinwoo Ahn; Marshall Urist; Carol Prives
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

8.  Questioning the role of checkpoint kinase 2 in the p53 DNA damage response.

Authors:  Jinwoo Ahn; Marshall Urist; Carol Prives
Journal:  J Biol Chem       Date:  2003-03-24       Impact factor: 5.157

9.  Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor.

Authors:  Changwook Lee; Jeong Ho Chang; Hyun Sook Lee; Yunje Cho
Journal:  Genes Dev       Date:  2002-12-15       Impact factor: 11.361

10.  Chk2 activates E2F-1 in response to DNA damage.

Authors:  Craig Stevens; Linda Smith; Nicholas B La Thangue
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

View more
  60 in total

1.  DNA damage signals through differentially modified E2F1 molecules to induce apoptosis.

Authors:  Jasmyne Carnevale; Oliva Palander; Laurie A Seifried; Frederick A Dick
Journal:  Mol Cell Biol       Date:  2011-12-19       Impact factor: 4.272

2.  Yox1 links MBF-dependent transcription to completion of DNA synthesis.

Authors:  Blanca Gómez-Escoda; Tsvetomira Ivanova; Isabel A Calvo; Isabel Alves-Rodrigues; Elena Hidalgo; José Ayté
Journal:  EMBO Rep       Date:  2010-12-03       Impact factor: 8.807

3.  Methylation of the retinoblastoma tumor suppressor by SMYD2.

Authors:  Louis A Saddic; Lisandra E West; Aaron Aslanian; John R Yates; Seth M Rubin; Or Gozani; Julien Sage
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

Review 4.  Life and death decisions by the E2F transcription factors.

Authors:  Phillip J Iaquinta; Jacqueline A Lees
Journal:  Curr Opin Cell Biol       Date:  2007-11-26       Impact factor: 8.382

Review 5.  Epigenetic regulation of human retinoblastoma.

Authors:  Usha Singh; Manzoor Ahmad Malik; Sandeep Goswami; Swati Shukla; Jasbir Kaur
Journal:  Tumour Biol       Date:  2016-09-17

Review 6.  Transcriptional responses to DNA damage.

Authors:  Erica Silva; Trey Ideker
Journal:  DNA Repair (Amst)       Date:  2019-05-07

7.  Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss.

Authors:  Madhav Sankunny; Rahul A Parikh; Dale W Lewis; William E Gooding; William S Saunders; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2013-11-25       Impact factor: 5.006

8.  Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation.

Authors:  Jin Xiang; Chang Chen; Rui Liu; Dongmei Gou; Lei Chang; Haijun Deng; Qingzhu Gao; Wanjun Zhang; Lin Tuo; Xuanming Pan; Li Liang; Jie Xia; Luyi Huang; Ke Yao; Bohong Wang; Zeping Hu; Ailong Huang; Kai Wang; Ni Tang
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

9.  Vitamin D - a new treatment for airway remodelling in asthma?

Authors:  Rachel L Clifford; Alan J Knox
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

Review 10.  The rb pathway and cancer therapeutics.

Authors:  W Du; J S Searle
Journal:  Curr Drug Targets       Date:  2009-07       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.